Search form

Search form

A dual-hormone closed-loop delivery system fared better than traditional pump treatment in improving glycemic control and curbing hypoglycemia risk in diabetes patients, researchers wrote in the Canadian Medical Association Journal. The system also helped increase how long patients spent at target plasma glucose levels, they added.

Related Summaries

Total insulin requirements were 14 percentage points lower during closed-loop insulin delivery in the daytime, compared with the coefficient variation for overnight, while overnight insulin requirements were 9 percentage points higher than daytime, according to a study in Diabetes Care. UK researchers used a cohort of 32 type 1 diabetes patients involved in a multicenter closed-loop trial.

A study presented at the World Diabetes Congress revealed adolescent type 1 diabetes patients who used a closed-loop continuous glucose monitoring system attained lower mean glucose levels and fewer nocturnal hypoglycemia incidents compared with those who used sensor-augmented pump therapy. Patients who used the artificial pancreas also had more time in blood glucose targets than the sensor-augmented pump arm, researchers noted.

Data on 26,636 type 2 diabetes patients showed those with poor control over A1C, systolic blood pressure and low-density lipoprotein cholesterol, as well as those with only good A1C control, had the highest rate of cardiovascular disease-related hospitalizations after 5.6 years. Those whose three risk factors were well-controlled had the lowest hospitalization rates. The findings appear in the Journal of General Internal Medicine.

Type 1 diabetes patients using a closed-loop insulin delivery system who added preprandial pramlintide injections showed better blood glucose control than those who did not, according to a study in Diabetes Care. Researchers also noted significant improvements in the mean magnitude of glycemic excursion of pramlintide-treated patients.

Children younger than 7 with type 1 diabetes who were on closed-loop insulin therapy showed significant improvements in nocturnal glycemic control, a study presented at the American Diabetes Association 72nd Scientific Sessions showed. Researchers also found that closed-loop insulin did not increase the risk of hypoglycemia and improved prelunch blood glucose levels in patients.